Surgery, Gastroenterology and Oncology
Vol. 26, No. 4, Dec 2021
An IL8-CEA Combined Score is Stage-Specific in Colorectal Cancer
Ashok Gunawardene, Stephanie Manning, Ana Holley, Gisela Kristono, Kirsty Danielson, Ali Shekouh, Peter Larsen, Elizabeth Dennett
ORIGINAL PAPER, Dec 2021
Article DOI: 10.21614/sgo-26-4-401
Background: A raised pre-treatment carcinoembryonic antigen (CEA) level is frequently observed in colorectal cancer patients with metastatic disease and is thought to be a reflection of disease burden. Additionally, there is a growing body of evidence highlighting the influence of a pro-inflammatory host-response on colorectal cancer progression. Proinflammatory cytokines IL-1 , IL-6, IL-8 and TNF have been implicated in this relationship through experimental and clinical studies. We set out to evaluate whether combining circulating inflammatory markers, such as these, with CEA improves upon the stagespecificity of CEA alone.

Methods: Sixty patients were enrolled prospectively at a single centre over a sixteen month period into three groups: control (n=19), stage II (n=22) and stage IV (n=19) colorectal cancer. Baseline levels of carcinoembryonic antigen (CEA) as well as plasma IL-1 , IL-6, IL-8 and TNF were compared across the groups. The ability of each marker to distinguish patients by disease status was evaluated using Receiver Operator Characteristic (ROC) curve and Chi-squared analysis.

Results: CEA, IL-6 and IL-8 increased significantly between the three groups. CEA and IL-8 were most effective in discriminating between stage II and stage IV disease groups. We found IL8-CEA score was more effective in discriminating between stage II and stage IV CRC (OR 10.3, 95% CI 1.1-92.2, p=0.01) compared with CEA alone (OR 5.4, 95% CI 1.3-27.8, p=0.01).

Conclusion: Combining IL-8 with CEA improved upon the stage-specificity of CEA alone. This suggests a potential value for combining circulating inflammatory biomarkers with CEA to accurately stage CRC.

Full Text Sources: Download pdf
Abstract:   Abstract EN
Views: 1460


Watch Video Articles


For Authors



Journal Subscriptions

Current Issue

Mar 2025

Supplements

Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)

e-ISSN: 2601 - 1700 (online)

ISSN-L: 2559 - 723X

Journal Abbreviation: Surg. Gastroenterol. Oncol.

Surgery, Gastroenterology and Oncology (SGO) is indexed in:
  • SCOPUS
  • EBSCO
  • DOI/Crossref
  • Google Scholar
  • SCImago
  • Harvard Library
  • Open Academic Journals Index (OAJI)

Open Access Statement

Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.

Journal Metrics

Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2



Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019

Creative Commons License
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/